Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. (Record no. 19452386)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 02367 a2200673 4500 |
005 - DATE AND TIME OF LATEST TRANSACTION | |
control field | 20250515203229.0 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 201002s 0 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
International Standard Serial Number | 1474-547X |
024 7# - OTHER STANDARD IDENTIFIER | |
Standard number or code | 10.1016/S0140-6736(09)62041-9 |
Source of number or code | doi |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | NLM |
Language of cataloging | eng |
Transcribing agency | NLM |
100 1# - MAIN ENTRY--PERSONAL NAME | |
Personal name | Eron, Joseph J |
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
Date of production, publication, distribution, manufacture, or copyright notice | 20100218 |
245 00 - TITLE STATEMENT | |
Title | Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. |
Medium | [electronic resource] |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Name of publisher, distributor, etc. | Lancet (London, England) |
Date of publication, distribution, etc. | Jan 2010 |
300 ## - PHYSICAL DESCRIPTION | |
Extent | 396-407 p. |
Other physical details | digital |
500 ## - GENERAL NOTE | |
General note | Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Adult |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Anti-HIV Agents |
General subdivision | adverse effects |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Cholesterol, LDL |
General subdivision | blood |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Double-Blind Method |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Drug Administration Schedule |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Drug Therapy, Combination |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Female |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | HIV Infections |
General subdivision | blood |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | HIV-1 |
General subdivision | drug effects |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Humans |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Lopinavir |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Male |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Middle Aged |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Pyrimidinones |
General subdivision | adverse effects |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Pyrrolidinones |
General subdivision | adverse effects |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | RNA, Viral |
General subdivision | blood |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Raltegravir Potassium |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Ritonavir |
General subdivision | adverse effects |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Treatment Outcome |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Viremia |
General subdivision | physiopathology |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Young, Benjamin |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Cooper, David A |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Youle, Michael |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Dejesus, Edwin |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Andrade-Villanueva, Jaime |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Workman, Cassy |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Zajdenverg, Roberto |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Fätkenheuer, Gerd |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Berger, Daniel S |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Kumar, Princy N |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Rodgers, Anthony J |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Shaughnessy, Melissa A |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Walker, Monica L |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Barnard, Richard J O |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Miller, Michael D |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Dinubile, Mark J |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Nguyen, Bach-Yen |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Leavitt, Randi |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Xu, Xia |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Sklar, Peter |
773 0# - HOST ITEM ENTRY | |
Title | Lancet (London, England) |
Related parts | vol. 375 |
-- | no. 9712 |
-- | p. 396-407 |
856 40 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="https://doi.org/10.1016/S0140-6736(09)62041-9">https://doi.org/10.1016/S0140-6736(09)62041-9</a> |
Public note | Available from publisher's website |
No items available.